Puma Biotechnology
PBYI
110 hedge funds and large institutions have $948M invested in Puma Biotechnology in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 28 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
6% more capital invested
Capital invested by funds: $893M → $948M (+$54.8M)
4.28% more ownership
Funds ownership: 93.61% → 97.9% (+4.3%)
8% less funds holding
Funds holding: 119 → 110 (-9)
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
43% less call options, than puts
Call options by funds: $3.89M | Put options by funds: $6.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$46M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$18.6M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
+$18.4M |
| 4 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$14.1M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
-$59.1M |
| 2 |
Millennium Management
New York
|
-$26M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.6M |
| 4 |
VAM
Visium Asset Management
New York
|
-$6.34M |
| 5 |
CCM
Cornerstone Capital Management
Edina,
Minnesota
|
-$3.95M |
PBYI Hedge Fund Activity: Q2 2016 in Review
110 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2016, worth a combined $948M — up 6.1% from $893M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of PBYI and 20 opened new positions — a net loss of 8 holders — while 28 trimmed existing stakes and 43 added.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $46M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), exiting entirely with an estimated $59.1M sold.
- 110 institutional investors held Puma Biotechnology (PBYI) as of Q2 2016, down from 119 in Q1 2016.
- Funds reported $948M of Puma Biotechnology stock for Q2 2016, up 6.1% quarter-over-quarter.
- 20 funds opened new Puma Biotechnology positions in Q2 2016 and 28 closed out, a net change of -8 holders.
- The largest Puma Biotechnology buyer in Q2 2016 was PFM Health Sciences, an estimated $46M added.
- The largest Puma Biotechnology seller in Q2 2016 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $59.1M sold.
Based on aggregated 13F filings for Q2 2016.